PMID- 18271936
OWN - NLM
STAT- MEDLINE
DCOM- 20080422
LR  - 20201226
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 99
IP  - 2
DP  - 2008 Feb
TI  - Prognostic impact and immunogenicity of a novel osteosarcoma antigen, 
      papillomavirus binding factor, in patients with osteosarcoma.
PG  - 368-75
LID - 10.1111/j.1349-7006.2008.00695.x [doi]
AB  - To develop peptide-based immunotherapy for osteosarcoma, we previously identified 
      papillomavirus binding factor (PBF) as a cytotoxic T lymphocytes (CTL)-defined 
      osteosarcoma antigen in the context of human leukocyte antigen (HLA)-B55. In the 
      present study, we analyzed the distribution profile of PBF in 83 biopsy specimens 
      of osteosarcomas and also the prognostic impact of PBF expression in 78 patients 
      with osteosarcoma who had completed the standard treatment protocols. Next, we 
      determined the antigenic peptides from PBF that react with peripheral T 
      lymphocytes of HLA-A24(+) patients with osteosarcoma. Immunohistochemical 
      analysis revealed that 92% of biopsy specimens of osteosarcoma expressed PBF. 
      PBF-positive osteosarcoma conferred significantly poorer prognosis than those 
      with negative expression of PBF (P = 0.025). In accordance with the 
      Bioinformatics and Molecular Analysis Section score, we synthesized 10 peptides 
      from the PBF sequence. Subsequent screening with an HLA class I stabilization 
      assay revealed that peptide PBF A24.2 had the highest affinity to HLA-A24. CD8(+) 
      T cells reacting with a PBF A24.2 peptide were detected in eight of nine 
      HLA-A24-positive patients with osteosarcoma at the frequency from 5 x 10(-7) to 7 
      x 10(-6) using limiting dilution/mixed lymphocyte peptide culture followed by 
      tetramer-based frequency analysis. PBF A24.2 peptide induced CTL lines from an 
      HLA-A24-positive patient, which specifically killed an osteosarcoma cell line 
      that expresses both PBF and HLA-A24. These findings suggested prognostic 
      significance and immunodominancy of PBF in patients with osteosarcoma. PBF is the 
      candidate target for immunotherapy in patients with osteosarcoma.
FAU - Tsukahara, Tomohide
AU  - Tsukahara T
AD  - Department of Orthopaedic Surgery, Sapporo Medical Unviersity School of Medicine, 
      South-1, West-16, Chuo-ku, Sapporo, Japan.
FAU - Kawaguchi, Satoshi
AU  - Kawaguchi S
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Kimura, Shigeharu
AU  - Kimura S
FAU - Murase, Masaki
AU  - Murase M
FAU - Ichimiya, Shingo
AU  - Ichimiya S
FAU - Wada, Takuro
AU  - Wada T
FAU - Kaya, Mitsunori
AU  - Kaya M
FAU - Nagoya, Satoshi
AU  - Nagoya S
FAU - Ishii, Takeshi
AU  - Ishii T
FAU - Tatezaki, Shin-ichiro
AU  - Tatezaki S
FAU - Yamashita, Toshihiko
AU  - Yamashita T
FAU - Sato, Noriyuki
AU  - Sato N
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Transcription Factors)
RN  - 0 (ZNF395 protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Antigens, Neoplasm/*immunology/metabolism
MH  - Bone Neoplasms/*diagnosis/*immunology/metabolism
MH  - Child
MH  - DNA-Binding Proteins/*immunology/metabolism
MH  - Female
MH  - HLA-A Antigens/genetics/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Osteosarcoma/*diagnosis/*immunology/metabolism
MH  - Prognosis
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Transcription Factors/*immunology/metabolism
EDAT- 2008/02/15 09:00
MHDA- 2008/04/23 09:00
CRDT- 2008/02/15 09:00
PHST- 2008/02/15 09:00 [pubmed]
PHST- 2008/04/23 09:00 [medline]
PHST- 2008/02/15 09:00 [entrez]
AID - CAS695 [pii]
AID - 10.1111/j.1349-7006.2008.00695.x [doi]
PST - ppublish
SO  - Cancer Sci. 2008 Feb;99(2):368-75. doi: 10.1111/j.1349-7006.2008.00695.x.